About Us

Glycemicon AG is a Swiss biotechnology company developing novel nutraceuticals for managing prediabetes, diabetes and obesity, using new approaches that were initially developed at the University of Science & Technology ETH Zurich. The lead product’s active substance is a naturally-occurring bile acid, THBA, which drives changes to the body fat architecture that combat elevated blood glucose levels.

Glycemicon stands for "glycemic control" - the maintenance of healthy blood sugar levels, which is the aim of every individual living with prediabetes and diabetes.

Our Team

THBA - Our lead substance

Glycemicon’ s lead substance, THBA, is a type of bile acid that is naturally occurring. It improves the body fat composition for managing diabetes by modifying body fat tissue, making it more efficient in decreasing elevated blood sugar levels.

Learn more

The company has completed successful pre-clinical studies with THBA to demonstrate efficacy and a clean safety profile, and will run clinical trials for both humans and pets in 2017. The first nutraceutical product could be used either on its own or in co-administration with current anti-diabetic therapies. The company was founded in 2013 financed mainly by private high net worth individuals.

As a spin-off company from the Federal Institute of Technology/ETH Zürich, we combine strong expertise in adipose tissue biology, diabetes and obesity with the top-notch synthetic chemistry of natural products and small molecules. Close interactions with academic collaboration partners, such as the ETH, will fuel our pipeline with innovative new approaches and molecules to tackle the epidemic of prediabetes, type 2 diabetes and obesity.